Skip to Content
AP-National

Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024

By
Published 7:20 AM

By TOM MURPHY
AP Health Writer

The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker expects 2024 to turn out largely better than expected too, as new products build momentum. Lilly said on Tuesday that company revenue could climb as much as 22%  and surpass $41 billion this year. Analysts expect sales to continue to build for Mounjaro and the company’s weight-loss drug Zepbound, which regulators approved in November. Zepound is a new version of Mounjaro that is debuting in  a hot area of medicine, chronic weight management. Analysts expect Zepbound sales to approach $2 billion this year.

Article Topic Follows: AP-National

Jump to comments ↓

Associated Press

Related Articles

BE PART OF THE CONVERSATION

KVIA ABC 7 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content